logo
UnitedHealth Stock Collapse Continues: Here's What This Investor Thinks Will Happen Next

UnitedHealth Stock Collapse Continues: Here's What This Investor Thinks Will Happen Next

UnitedHealth (NYSE:UNH) is coming off another bruising week, with shares down 7% – bringing the 12-month decline to a steep 50% – as a string of PR crises continues to weigh heavily on investor sentiment.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Since the assassination of Brian Thompson, the CEO of its insurance division, in New York last year, the company has faced mounting scrutiny. Investors are increasingly uneasy about UnitedHealth's transparency, while the public has raised sharp concerns over its claims-handling practices.
Given the reputational setbacks, investor A.J. Button believes the fallout could soon weigh on the company's bottom line.
'Bad PR can lead to brand damage,' he warns, 'which in turn can lead to policyholders taking their business elsewhere.'
That said, Button acknowledges that the company's fundamentals remain relatively strong. UNH still boasts a robust balance sheet and solid profitability metrics, suggesting it has the financial strength to withstand pressure. 'Nevertheless,' Button cautions, 'the issues facing UnitedHealth right now are very real.'
One of the most pressing red flags is the company's exceptionally high claim denial rate, reportedly the highest in the sector, according to multiple sources. While not catastrophic in itself, such a pattern could indicate flawed underwriting or strained claims infrastructure – issues that compound the reputational damage and hint at possible internal mismanagement.
'So,' Button adds, 'UnitedHealth has many qualities, good and bad.' On one hand, its financial footing and history of profitability provide a cushion. On the other, cracks are beginning to show: for fiscal 2024, its combined ratio hit 97.2% – right up against the industry's red line. Button argues that, before investors can have full confidence, the company needs to take meaningful action to shore up its underwriting performance.
Whether that turnaround is underway remains an open question. UnitedHealth recently reinstated former CEO Stephen Helmsley, following the previous leader's departure. But the move has raised eyebrows, given that Helmsley is a longtime insider who presided over many of the company's earlier challenges. His return doesn't exactly scream transformation.
A rebound is still possible – especially if the company takes decisive steps to restore trust and address internal inefficiencies. However, given the scale of its current controversies, Button advises investors to weigh the risks carefully. Even the stock's seemingly low P/E ratio doesn't present a compelling bargain relative to peers in the life and health insurance space.
'When considering a stock like UnitedHealth, with a good track record but an unprecedented new set of risk factors, it pays to be cautious,' the investor summed up.
Can UnitedHealth Stock Bounce Back?
Button assigns a 'low-conviction' buy rating on UNH shares – a nod to its potential, but with more than a few strings attached. (To watch Button's track record, click here)
Wall Street, though, is a bit more upbeat. The stock holds 19 Buy recommendations, 6 Holds, and just 1 Sell, translating to a Moderate Buy consensus rating. With an average price target of $364.96, analysts are eyeing 29% upside from current levels. (See UNH stock forecast)
To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

J.P. Morgan downgrades Bilibili, Inc. Class Z (9626) to a Hold
J.P. Morgan downgrades Bilibili, Inc. Class Z (9626) to a Hold

Business Insider

time35 minutes ago

  • Business Insider

J.P. Morgan downgrades Bilibili, Inc. Class Z (9626) to a Hold

J.P. Morgan analyst downgraded Bilibili, Inc. Class Z to a Hold today and set a price target of HK$185.00. The company's shares closed last Friday at HK$184.80. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bilibili, Inc. Class Z with a HK$201.50 average price target. The company has a one-year high of HK$238.80 and a one-year low of HK$98.90. Currently, Bilibili, Inc. Class Z has an average volume of 5.21M.

Netease Inc (9999) was downgraded to a Hold Rating at J.P. Morgan
Netease Inc (9999) was downgraded to a Hold Rating at J.P. Morgan

Business Insider

time35 minutes ago

  • Business Insider

Netease Inc (9999) was downgraded to a Hold Rating at J.P. Morgan

In a report released today, from J.P. Morgan downgraded Netease Inc to a Hold, with a price target of HK$220.00. The company's shares closed last Friday at HK$213.00. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Currently, the analyst consensus on Netease Inc is a Moderate Buy with an average price target of HK$228.60. The company has a one-year high of HK$222.80 and a one-year low of HK$116.00. Currently, Netease Inc has an average volume of 7.07M.

New Buy Rating for Mphasis Limited (MPHASIS), the Technology Giant
New Buy Rating for Mphasis Limited (MPHASIS), the Technology Giant

Business Insider

time2 hours ago

  • Business Insider

New Buy Rating for Mphasis Limited (MPHASIS), the Technology Giant

In a report released today, Nitin Padmanabhan from Investec maintained a Buy rating on Mphasis Limited, with a price target of INR2,980.00. The company's shares closed last Friday at INR2,631.10. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Padmanabhan covers the Technology sector, focusing on stocks such as LTIMindtree Limited, L&T Technology Services Ltd., and Mphasis Limited. According to TipRanks, Padmanabhan has an average return of 8.3% and a 56.25% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mphasis Limited with a INR2,908.11 average price target, a 10.53% upside from current levels. In a report released on July 25, Jefferies also upgraded the stock to a Buy with a INR3,100.00 price target.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store